<SEC-DOCUMENT>0001708599-25-000091.txt : 20250811
<SEC-HEADER>0001708599-25-000091.hdr.sgml : 20250811
<ACCEPTANCE-DATETIME>20250811161018
ACCESSION NUMBER:		0001708599-25-000091
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250811
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250811
DATE AS OF CHANGE:		20250811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Serina Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001708599
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				821436829
		STATE OF INCORPORATION:			AL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38519
		FILM NUMBER:		251202086

	BUSINESS ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806
		BUSINESS PHONE:		(256) 327-9630

	MAIL ADDRESS:	
		STREET 1:		601 GENOME WAY
		STREET 2:		SUITE 2001
		CITY:			HUNTSVILLE
		STATE:			AL
		ZIP:			35806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgeX Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ser-20250811.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:640e5d95-12e4-4c67-8d9f-5cb7177afd7c,g:68850849-c0f1-44db-b9db-ab8608b99a39,d:1e69e9d29e594463b2d4326c1d6f86f7-->
<html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ser-20250811</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001708599</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ser-20250811.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001708599</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1e69e9d29e594463b2d4326c1d6f86f7_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;11, 2025</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Serina Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-38519</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">82-1436829</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">601 Genome Way</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 2001</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Huntsville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">35806</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">(256)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">327-9630</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">SE</ix:nonNumeric>R</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">NYSE American</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e69e9d29e594463b2d4326c1d6f86f7_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">August&#160;11, 2025</ix:nonNumeric>, Serina Therapeutics, Inc issued a press release announcing its financial results for the quarter ended June&#160;30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="i1e69e9d29e594463b2d4326c1d6f86f7_7"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 - Financial Statements and Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm">Press Release of Serina Therapeutics, Inc. issued o</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm">n </a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm">August</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm"> 1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm">1</a><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="ser-20250811xex991_earning.htm">, </a></span><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (embedded within the Inline XBRL document) </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1e69e9d29e594463b2d4326c1d6f86f7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.477%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">SERINA THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-25">August&#160;11, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:114%">/s/ Gregory S. Curhan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ser-20250811xex991_earning.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i349c9351e18a40518d474dd6b1e8029b_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt;text-align:justify"><img alt="serina.jpg" src="serina.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:297px"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">HUNTSVILLE, August&#160;11, 2025 (GLOBE NEWSWIRE) &#8212; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Serina Therapeutics, Inc.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Serina&#8221;) (NYSE American&#58; SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform&#8482; drug optimization technology, today announced its financial results for the second quarter ended June&#160;30, 2025, along with key recent updates.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We&#8217;re proud of the momentum we&#8217;ve built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurological conditions with high unmet need,&#8221; said Steve Ledger, CEO of Serina Therapeutics. &#8220;We believe our proprietary polymer technology can unlock best-in-class treatment profiles and improve patient outcomes in ways not achievable with existing drug delivery approaches.&#34;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advancement of SER-270 for Tardive Dyskinesia&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025, Serina announced the advancement of SER-270 (POZ-VMAT2i), a once-weekly injectable therapy for tardive dyskinesia (TD), enabled by the POZ Platform. The program aims to address unment needs in TD treatment, particularly for institutional use and adherence challenges. SER-270 may also be evaluated for Huntington's disease chorea, a high need indication with limited long-acting injectable (LAI) options.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Board Appointments&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2025, Serina appointed </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Stephen (Steve) Brannan, M.D.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> to its Board of Directors. Mr. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization. Dr. Brannan held senior leadership roles at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly, focusing on clinical programs for depression, Alzheimer's, schizophrenia, and epilepsy. Most recently, as Chief Medical Officer at Karuna Therapeutics, he led the clinical strategy for KarXT (xanomeline&#8211;trospium), the first new schizophrenia treatment in over 30 years, which was key in Karuna&#8217;s $14 billion acquisition by Bristol Myers Squibb in 2024. This</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> addition strengthens Serina&#8217;s Board as the company advances its innovative therapeutic pipeline toward the clinic.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">$5 Million in Funding&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Financing via ATM&#58;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In April 2025, Serina entered into a Capital on Demand&#8482; Sales Agreement with JonesTrading Institutional Services LLC with respect to an at the market offering program under which the Company may offer and sell  $13.3 million of shares of Serina common stock in &#34;at-the-market&#34; (ATM) offerings. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of August 8, 2025, Serina issued 199,562 shares of common stock at a gross average price of $5.95, resulting in net proceeds of $1.2 million.</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter Operating Results</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Re</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">venues&#58; Revenues were $130 thousand for three months ended June 30, 2025, compared to $51 thousand for the same period in 2024. Revenues were comprised entirely of grant revenues from the National Institutes of Health.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating expenses&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Operating expenses for the three months ended June 30, 2025 and 2024 were $5.7 million and $3.9 million, respectively.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (R&#38;D) Expenses</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#58; R&#38;D expenses were $3.2 million for the three months ended June 30, 2025, compared to $1.6 million for the same period in 2024. The increase of $1.6 million is primarily driven by increases in outside research services, consultant spend for research programs and an increase in salaries, payroll related expenses and stock based compensation as a result of increased headcount. These increases were partially offset by decreases in professional fees for the maintenance of certain patent and other intellectual property and biological material assets included in Legacy Assets and severance related costs. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.5 million for the three months ended June 30, 2025, compared to $2.3 million for the same period in 2024. The  increase of $0.2 million is due primarily to increases of stock based compensation expenses as a result of new option grants, and financial consulting expenses primarily due to the deployment of new platforms and software. These increases were partially offset by a decrease in legal fees primarily as the result of the conclusion of our post-merger compliance and reporting activities. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income, Net&#58; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net was $0.9 million for the three months ended June 30, 2025 compared to  $9.0 million net income for the same period in 2024. The $9.9 million increase in expenses was primarily attributable </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$10.3 million change in fair value of liability classified warrants, offset by the decrease of $0.3 million in interest expense.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net (Loss) Income&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The net loss attributable to Serina for the three months ended June 30, 2025 was $6.4 million, or $(0.66) per basic and diluted share, compared to net income of $5.2 million, or $0.61 per basic share and $0.51 per diluted share for 2024. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity Information</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents totaled $6.0 million as of June&#160;30, 2025. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company projects its cash and cash equivalents as of June&#160;30, 2025 to fund operations into the fourth quarter of 2025.</font></div><div style="margin-top:16pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About Serina Therapeutics</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina&#8217;s POZ Platform</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About the POZ Platform&#8482;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Serina&#8217;s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina&#8217;s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina&#8217;s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Serina&#8217;s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina&#8217;s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About SER-252 (POZ-apomorphine)</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SER 252 is an investigational apomorphine therapy developed with Serina&#8217;s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson&#8217;s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans to advance SER 252 to clinical testing in 2025.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">About SER-270 (POZ-VMAT2i)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">SER-270 is an investigational once-weekly VMAT2 inhibitor developed with Serina&#8217;s POZ platform to address adherence and access challenges in tardive dyskinesia. TD is a disabling movement disorder often caused by long-term exposure to </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">antipsychotic medications. The subcutaneous formulation of SER-270 is designed for patients on long-acting injectable antipsychotics, those with dysphagia, and institutionalized populations and other patients with challenged adherence. Serina is also exploring development in Huntington&#8217;s disease chorea.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please visit </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https&#58;&#47;&#47;serinatherapeutics.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statement</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">References in this Report to &#8220;Serina,&#8221; &#8220;the Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221; refer to Serina Therapeutics, Inc.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This release contains forward-looking statements within the meaning of federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates&#8221;) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in Serina&#8217;s periodic reports filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) under the heading &#8220;Risk Factors&#8221; and other filings that Serina may make with the SEC. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, Serina disclaims any intent or obligation to update these forward-looking statements. These statements are based on management&#8217;s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina&#8217;s POZ polymer technology, Serina&#8217;s estimates regarding future revenue, expenses, capital requirements and need for additional financing, the sufficiency of Serina&#8217;s existing cash and cash equivalents to support operations into the fourth quarter of 2025, and Serina&#8217;s planned clinical programs, including planned clinical trials, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and&#47;or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and&#47;or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data&#59; Serina&#8217;s ability to continue as a going concern&#59; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities&#59; whether regulatory authorities will be satisfied with the design of and results from our clinical studies&#59; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions&#59; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product&#8217;s benefits outweigh its known risks and determination of the product&#8217;s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful&#59; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and&#47;or other matters that could affect the availability or commercial potential of any drug or vaccine candidates&#59; and competitive developments. These risks as well as other risks are more fully discussed in the company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, and the company&#8217;s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">For inquiries, please contact&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stefan Riley</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">sriley&#64;serinatherapeutics.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">(256) 327-9630</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i349c9351e18a40518d474dd6b1e8029b_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Unaudited) </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">June 30, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,672&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,950&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,004&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,991&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,676&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">588&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">501&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right of use assets - operating leases</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">362&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Right of use assets - finance leases</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">86&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL ASSETS</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,941&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,724&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,706&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">744&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,310&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,429&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">545&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,561&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,366&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Warrant liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,549&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,582&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">185&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">268&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL LIABILITIES</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">7,295&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,216&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Series A convertible preferred stock</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">4,940&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:7.37pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Common stock</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">52,440&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">44,958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(55,579)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(44,318)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total Serina Therapeutics, Inc. stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,802&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">641&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Noncontrolling interest</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(156)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(133)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,646&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">508&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,941&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,724&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i349c9351e18a40518d474dd6b1e8029b_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Three months ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Six months ending<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">REVENUES</font></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Grant revenues</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">130&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">51&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">130&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">OPERATING EXPENSES</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">1,594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,700&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,543&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">2,323&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,543&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,695&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,917&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">11,553&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">6,243&#160;</font></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(5,565)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,866)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,423)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,187)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">OTHER (EXPENSE) INCOME, NET</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(307)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(493)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value of convertible promissory notes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(7,017)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value of warrants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(956)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,294&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">3,716&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">68&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">115&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">143&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Total other (expense) income, net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(897)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,043&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">139&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(3,651)</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">NET (LOSS) INCOME </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,462)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,177&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,284)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,838)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">Net loss attributable to noncontrolling interest</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">23&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">NET (LOSS) INCOME ATTRIBUTABLE TO SERINA THERAPEUTICS, INC.</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(6,448)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,204&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(11,261)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(9,811)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">NET (LOSS) INCOME PER COMMON SHARE&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BASIC</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.66)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.61&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.15)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.74)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">DILUTED</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(0.66)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">0.51&#160;</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.15)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">(1.74)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">BASIC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,004</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">8,514</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,883</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,652</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">DILUTED</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,004</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">10,157</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">9,883</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:114%">5,652</font></td></tr></table></div><div style="margin-top:8pt;text-align:center"><font><br></font></div><div id="i349c9351e18a40518d474dd6b1e8029b_10"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SERINA THERAPEUTICS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(unaudited)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Six months ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">OPERATING ACTIVITIES&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(11,284)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(9,838)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">82&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash lease expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">116&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on convertible promissory note</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">163&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Amortization of debt issuance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">511&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Common stock issued to consultant for services rendered</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">60&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Restricted stock units released to consultant for services rendered</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">29&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of convertible promissory notes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,017&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Change in fair value of warrants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(33)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(3,716)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(2,679)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,204)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(115)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(194)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Accrued interest on convertible promissory notes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(105)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(112)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">368&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(61)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(8,072)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(9,586)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">INVESTING ACTIVITIES&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Purchase of equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(46)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(46)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(14)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">FINANCING ACTIVITIES&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Drawdown on loan facilities from Juvenescence</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Cash and restricted cash acquired in connection with the Merger</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">337&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercise of Post-Merger Warrants by Juvenescence</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercise of stock options</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from issuance of stock to Juvenescence, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,916&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Principal repayment on loan facilities to Juvenescence</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(133)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Principal repayments on finance lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(26)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from issuance of Series A convertible preferred stock, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">4,940&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from issuance of common stock under at-the-market sales agreement, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">629&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">10,487&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">8,095&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">NET CHANGE IN CASH AND CASH EQUIVALENTS</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">2,369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">(1,505)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%">CASH AND CASH EQUIVALENTS&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">At beginning of the period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">3,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">7,619&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">At end of the period</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,041&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">6,114&#160;</font></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:114%">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of common stock upon conversion of redeemable convertible preferred stock</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">36,404&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Merger and issuance of common stock upon consummation of Merger on March 26, 2024</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Deemed dividend from issuance of warrants</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">18,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Issuance of warrants upon exercise of Post-Merger warrants</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">1,372&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Transfer of right&#8209;of&#8209;use assets to property and equipment upon title transfer</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ser-20250811.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:640e5d95-12e4-4c67-8d9f-5cb7177afd7c,g:68850849-c0f1-44db-b9db-ab8608b99a39-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ser="http://serinatherapeutics.com/20250811" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://serinatherapeutics.com/20250811">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20250811_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ser-20250811_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://serinatherapeutics.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ser-20250811_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:640e5d95-12e4-4c67-8d9f-5cb7177afd7c,g:68850849-c0f1-44db-b9db-ab8608b99a39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_5e3e3e8a-039d-4d09-ad40-7915b5ed07ed_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_69fd9454-0de4-498e-ba24-60b6b7461994_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bdfac3ee-c481-4b1a-bd23-b149df212f2e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cd2b9d58-6881-42b7-8c11-447e4d519dc1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e07c60ba-56dc-416e-889b-c7d20c0a1edc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_e96a3551-4929-4cb9-9ff2-22f3efe857ca_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3fcc5356-0969-4eef-953c-6d0e6e6bcda1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_058db8fc-6a5d-4f48-9755-16abbc8af47a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_11a2a3f5-1c15-4285-96d9-66941939a2f0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e5617b20-5144-448f-b720-79e2ac523265_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_986b68f1-efad-4b06-b9bd-264b975fb562_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2fb4bdfa-79cf-4ad0-a923-04c32d76f0d1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_825fd547-e3d5-4e61-a906-cf8b2f816c18_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9cf50cc2-d9cc-4ee9-bc69-bbe9c649fee6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bc2a38e7-5868-489d-a49c-435b44fca107_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_591b4c28-26b5-4d39-b8f5-d45e4cfde8d1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1764d9eb-c570-4494-91be-6a6c3a327661_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_19315452-0e94-4291-b47e-a222f00fb3c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_920fe699-6c77-4143-a043-61543902e125_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_45ce3118-a16f-42b2-932f-042ea2076a05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_caa4f0bc-d478-468c-a738-42a78f465fa5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e46b8028-cfb3-49e4-97df-63df83dd48cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9f56427d-5527-4d0a-af72-01902466afe6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3fd42dc3-8702-4c84-9ac1-a3bac50b8b43_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ser-20250811_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:640e5d95-12e4-4c67-8d9f-5cb7177afd7c,g:68850849-c0f1-44db-b9db-ab8608b99a39-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serinatherapeutics.com/role/Cover" xlink:type="simple" xlink:href="ser-20250811.xsd#Cover"/>
  <link:presentationLink xlink:role="http://serinatherapeutics.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_81cd16de-4446-4451-bf9f-b3eba0dbd664" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_DocumentType_81cd16de-4446-4451-bf9f-b3eba0dbd664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_404111b7-4b78-4815-b4f2-7bb3ecf68403" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_DocumentPeriodEndDate_404111b7-4b78-4815-b4f2-7bb3ecf68403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cd461f2b-00d4-42fd-be4c-8b2bd5875c9f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityRegistrantName_cd461f2b-00d4-42fd-be4c-8b2bd5875c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_de5eeb9b-a667-4fc0-8d39-990572f6d912" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityIncorporationStateCountryCode_de5eeb9b-a667-4fc0-8d39-990572f6d912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6ba3dae2-050d-4f2b-8b5a-aa61cce83188" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityFileNumber_6ba3dae2-050d-4f2b-8b5a-aa61cce83188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f2999bce-a865-419f-8a86-3be4804704fc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityTaxIdentificationNumber_f2999bce-a865-419f-8a86-3be4804704fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_bfb182fb-80da-427c-9037-83b9f28c8f0f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityAddressAddressLine1_bfb182fb-80da-427c-9037-83b9f28c8f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e581974f-b553-4e87-ab79-aefc308b91cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityAddressAddressLine2_e581974f-b553-4e87-ab79-aefc308b91cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_67ea90a7-05e5-447e-8176-80513a517b63" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityAddressCityOrTown_67ea90a7-05e5-447e-8176-80513a517b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_cf1623be-9262-4286-8f71-7791ce2ce528" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityAddressStateOrProvince_cf1623be-9262-4286-8f71-7791ce2ce528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2176278b-a137-4bd9-8d89-9a7593476642" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityAddressPostalZipCode_2176278b-a137-4bd9-8d89-9a7593476642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e703fe10-c3bc-4be2-80dc-a5847c16de2c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_CityAreaCode_e703fe10-c3bc-4be2-80dc-a5847c16de2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_990d9176-8d1b-4785-b11e-f2f2d9da1c53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_LocalPhoneNumber_990d9176-8d1b-4785-b11e-f2f2d9da1c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2fa6cb52-b53e-4838-864b-b33b9745d66a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_WrittenCommunications_2fa6cb52-b53e-4838-864b-b33b9745d66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_aca22aad-6650-4940-ab5c-aff1444064c1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_SolicitingMaterial_aca22aad-6650-4940-ab5c-aff1444064c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_373c2f50-14a1-47af-a7d3-ecc2ef704ef1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_PreCommencementTenderOffer_373c2f50-14a1-47af-a7d3-ecc2ef704ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_dfafa59a-b53a-4ed3-a8f3-3dfed267bc5d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_dfafa59a-b53a-4ed3-a8f3-3dfed267bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3f7ab0ab-b1a8-4cf6-af9a-4f59bc1abe28" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_Security12bTitle_3f7ab0ab-b1a8-4cf6-af9a-4f59bc1abe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a236fb51-fd01-47a3-84ed-14e954e015c4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_TradingSymbol_a236fb51-fd01-47a3-84ed-14e954e015c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6edaba60-c89e-450e-a95c-0e0d4daf6a88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_SecurityExchangeName_6edaba60-c89e-450e-a95c-0e0d4daf6a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_696ecb3d-b3e4-49ef-b2bd-ac077345a230" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityEmergingGrowthCompany_696ecb3d-b3e4-49ef-b2bd-ac077345a230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_91328885-bec8-458b-8643-34991b7be7e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_EntityCentralIndexKey_91328885-bec8-458b-8643-34991b7be7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_be97e05f-5959-456f-b8e5-cbf9316e84ec" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4e3b5524-3050-4f54-9e8f-22684d51bd63" xlink:to="loc_dei_AmendmentFlag_be97e05f-5959-456f-b8e5-cbf9316e84ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>serina.jpg
<TEXT>
begin 644 serina.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #? O@# 2(  A$! Q$!_\0
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M6$T:]V2\^II"#LZ,BQXRM6M=2%RHPG!!K9BF75?"N^4@R*I.!5*\F_X2+0$
M8>9&<D'K@5G^&9_W-W"QXV8Q7'+$PP^+JRIOW)Q_%CLY05]TRQX#NDM[J5&.
M&8\53O#GQ(W^^:K:6OV?Q!"!P%>K,WS:^?=B:X:.)_V6A0E_R[E<U<??;[E[
MQI> ^1;_ ,10&KFEWRZ;X;+NNUFRHXK!\23"XU2W('"@#^57O$ETJZ;#;*,,
M,&M?[0Y:F(Q$7J]B?9W48E;PK;G4-5,K\E3DUH^-O$'G2?8X<@+\KTS1=FBZ
M.UVY"R2K@5FZ18R:YJOG.,INR];1K5883ZG2^.MJR>5<_.]D=+X+T1=/A^VS
MX!ZJ?:L[Q?XF;4)?LUN?W6<''7-2^*/$*V]I]@MSP!@XJOX2\-/>2_:[D8B7
M^%NOUKV:U2<J<,ERW9ZS?GU,U%)NM4^1H^#?"Q7%W<+R>F:Z36O$UOHMN<,"
M^. .:R_$7BJ'2[?R;<[GQCY>U<39V=YXBO=S[FW'EL<5[?\ :U'((1RW*H\U
M1[M:F/LW6?M*NB/5/#NLKK%FDN<L1DBM?-8GAW0XM%MPJ_?8<FMO@U^UY/+$
M2P</K7Q]3RJO+SOEV"EI*6O=,0HHHH *2EHH @NIA;V\LS=$4L?PKXN^-WC)
M_$_BZXB$C?9H6RJYQZU]DZW_ ,@F]_ZXM_*O@CQSQXAU''7M^=85#6F=9\+?
MA3=>/M0#.A2P0C>?NY'L:^F_#?P7\/\ AUX)8H"\L8Q^\PPJK\ H[5?AMI#1
M;3<&$>9CK^->D54(JQ,I-LS?^$;TS_GRM_\ OTO^%'_"-Z9_SXV__?I?\*TZ
M*TLB#D]>^&>A^(%(N+54_P"N:A:\)^*7[/;:/#+J&BJS1("S(3N8_05]0TWR
MPZX8 CT(J903*4FC\\+>XN=(U 2QEX;B%L$<@BOM/X/^-T\9>&8G9P980(SZ
M\"O!_C1\)-2L?$SW>F6DEQ%=%I'$29P:V_V<=)U[P_XD^R7=E<6]DZLY:1<#
M-8QO&5C25FKGTY1245TF)R?Q*\81^#?#-W>;U6X5-T8/<_2OB3Q%X@N_$NJ3
M7MS(TAD8LJY/?VKUO]I;Q2^HZU!IZ2[D@8JR@_6N'^$W@\^,/%MK 4W6P.'/
M8=*Y9-R=D;QLE<W?A?\  ^_\<1B\ND,%FK8*ME6/N*^A_#OP5\.^'XXQ% SL
MN"?,^;FNUTRPCTRRAMHU55C0+P/05;K6,$C-R;,W_A'--_Y\K?\ []+_ (4?
M\(WIG_/C;_\ ?I?\*TJ-U:61!R.N?#+0M?\ ]?:JA Q^[4+7A?Q2_9Z.AVLF
MH:*K,@.2C$L?RKZB_BILL:S*4=0RL,$&IE%,I2:/SOAFN=+O$D0R6]Q"^=O*
M\@U]@? WXC-XRT-(+IU-[$N7QQ7C7[17@'^P?$#:M:Q[;24*FT#^+N:YCX,>
M*)_#/C*W6.3;'>.L;_2N>-XNQJ_>1]O+Z4M-CD610R'<IZ$4ZNLP.5^)7_(J
M7?\ NG^1KX07_CXN/^NK?S-?=_Q*_P"15N_]T_R-?!_W9KD]O-?^9KEJ[F]/
M8ZK5/'%[J7A73= @W[+=R0L8.6R.G'6O0OAG^SS+XBM[>^U<-':R#=L!*OBL
MW]G_ ,!KXF\0&]N$W16^)$R.,U]>1QK$H55"J.@ JH1YM6*4K:(X?1_@WX=T
M4Q^3;EB@P-^#74+X:TQ5 %C;X'_3)?\ "M.@&MN5&5S/B\/Z?"X=+.!&'=8U
M!_E6AM HI:H0G3-?!GQ*_P"1ZU;_ *[M7WFW2O@SXE?\CUJW_7=JPJ[&M/<]
MO_95_P"0/<?]=C_6OH6OGK]E7_D#W'_78_UKZ%JX?"3+<*Y/XH_\B/JO_7*N
MLKD_BC_R(^J_]<JM[$H^%;Y=UY,/^F@->D?%/QU+XAATC2;%W>%;6-66,G[P
M ':O.KK_ (_;C_>KV#]G?X<QZ]JPU6]3S+>,E=I]>U<<;WLCH=MV6/AA^SS)
MXALX[[6 4A8\*#M:O;M(^#/AW1_*\J L8^1OP:[F&%(8E1%"JHP *?S75&*1
M@Y-F6OAG35&!96__ 'Z7_"JVI>"=(U2W,4MG$JG^Y& ?Y5NT55D*[/)/%7[/
M.@ZQ:NUNCQW&/E^; KYJ\=?#_4? VHO!=1EH<_+(HR/SK[OR:X[XH^#[;Q9X
M9N(IHU9HE:13CG(%9R@K%QDUH?(_PQ\93^#?$UN\<C"&=PC@G@"OM[1]2CU;
M3H;N)@T<@R"#7Y\:E9R:;<36\G#QDU]A_L^ZQ)J'@>RA?.(8P!FLZ<GL5-=3
MU&DS2TE=)B0WETMG;2S.<+&I8_A7QQ\:OB3=>*_$,UI#,1I\+94*<9^M?3GQ
M5U*ZT_PK<?9())Y9E:/;&,GD5\:V_@?7KJ[C273;G]X^"Q2L*C>QK!+=FM\-
M_AC?_$*]=85"6T1&]FXR/8U]+>%?@+H&@6Z;XFDFZL6.X9K:^$_A.'PQX4LX
MQ#Y=PR?O,CFNTZTXP26HI29F1^&M,2-4%E!A1@9B7_"G_P#".:;_ ,^-O_WZ
M7_"M*BM;(@YG6/A[HNMQJD]I&H!S^[0"O'OB)^SA:BUN;[1@RS ;MK-D?E7T
M-R*0_,#D9%2XICYFC\[[^QN=+O)+>=7@GB;!(RN?I7TY^SA\0GU;33I=[(6N
M5;Y#_LBN1_:<\'K8ZE:ZG;0[8=A,K =R:X+X,ZQ)I?C2)EE$,9B8[FZ5SKW)
M&S]Y'W#1245UG.,F7<I'2O,/$GA:]749[J+=(&;( %>H-][K3'C63@\U\EG^
M0T\\H^SGHSHHUG1=T>.V^L:GHK8<NB_W:Z/3OB/P$FB/^\378W6@V5T#YD*,
M?<5RVH?#N.1F:*0KW"@5^65,AXBR+WL%6YHKH>DJU"M\:.BT_P 36=]C;,NX
M]LUJ'9,N,Y%>27'A?5-+):%& '\0IEGXJO\ 37 D=I,=F-=.'XXQ.%_<YIAW
MZV)E@XRUIR/0M8\(VFI*Q"*LAZ-7GVJ>%KW2)S)$&8+T8=JZG2_B%#+M%SMB
M/UKHX=4L-5CPK+(#3Q>!R#B)>UPE54ZOJ*$Z]#22NC@=#\=3V'[JX#2X.,YZ
M5UZW-CXHM=A*L>N/2L_7?!%OJ#&2V_=''W5'6N+NK/4?#DW#/$N>H[UX$L5F
MN0IX;'0=>@^J70VY:5;WH.S+WB'PO-H\PGM_F0'/RCI5KP_XJW*;2]/F1OQE
MCTJ72?&45POD7ZJ5Z;F[U6U[0(IE^UZ?\T9YPHX%>&Y4\,WCLIG9=8=3?XER
M55\RKXDT,V,GVJV^:!OFW+T%36>H?V]8FSF.)%&58^U5M)UQH<VE]\\+'!W_
M ,-0:A9G3;@7-LY:(\[AQCVKY[$8RG3;K45RQ?Q1\^YM&+?NRW[B:3.VGWDD
M4GRAAMP:8[?V7J^U6Q'GGWJ#4+P7D@E V.,=*;;V=SJDA\M#*]?*O$UJ]J&&
MBY._0Z>51]Z6A-]I3^W#..(R^<U)/?*NH+.IW*,UHV?@6]GV>8C(#U]JT?\
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MZYFDP/B7XLWT=]X\U66)@R^;D8KV/]E7P_LLM0O7//F@C\J\!\6#=XJU3/\
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MC)Q=F4US*Z/M9:SO$7.BWN.?W9K0A8R0HQZLH-,NH5FMWC895A@UT]# _/\
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MBXCL9R<&*1N:UC-,S<&CU&BN?'C[P\?^8K;_ )G_  I?^$]\/_\ 05M_S/\
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M "H ^%_BC_R/.H?Y[FO8?V4_O:K_ ,!_I7CWQ2_Y'K4/\]S7L/[*?WM5_P"
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MU:4W#9W>1*O ]J]WAL;>WYBB5/\ =%3]:I4TA.=SR?X[>'I[CP#/8Z7:[P%
M6).G>OEM/ /B95 _LIZ^^9K>.X39*BNOHU5_['LO^?:/_OFB5.X1EREM?NCZ
M44M%:F9S7BCQ3'H>5(/F'@<<9QFN.E^(%Y(C !<_2NW\0>&8=<E4RCH<]?;%
M4X? &F1X)C8G_>K\@SK+^(L;BY+"34:=W]U]#TZ,\/"/O+4X:Y\5:G=(%V,
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M:],';<T;=6)KO=%\%VVGJK2#S'Z_,*Z&&TAM5 1%7Z#%8WB#Q1!I<+#=F3'
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MZ;G_ (_;?_OZO^-"BNX^9GR%_P )!XQ^$>KQK?-))"&'R2.2NW/7I7U/\/\
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M2Q7*K(P$I:**H HHHH **** "BBB@ K+\1>'[7Q)IDUG=1JZR*5&[MFM2DH
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 11,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Serina Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-38519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-1436829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Genome Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Huntsville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-9630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ser-20250811.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serinatherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="ser-20250811.htm">ser-20250811.htm</File>
    <File>ser-20250811.xsd</File>
    <File>ser-20250811_lab.xml</File>
    <File>ser-20250811_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ser-20250811.htm": {
   "nsprefix": "ser",
   "nsuri": "http://serinatherapeutics.com/20250811",
   "dts": {
    "inline": {
     "local": [
      "ser-20250811.htm"
     ]
    },
    "schema": {
     "local": [
      "ser-20250811.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ser-20250811_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ser-20250811_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://serinatherapeutics.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20250811.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ser-20250811.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serinatherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001708599-25-000091-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001708599-25-000091-xbrl.zip
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M<>*N[N3<\P23,OWO/8QG9:ZDEFM638N\94$(2/03G=YU)_D=\@>;9K.SV>J
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M<HHO41ZD;KPC0^ZC G()VJA8X($$5 A"&,>^H@$+8^E/B02,)(=3W3/M$ Z
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MXATI8R9V4O3:#T5?4O02,\I'[G:*GK;]2HG9%XO)%D!7$B0Q 6%6M*ZN1_N
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MB U>7DEGP<D:SH?#K\]YY5\):1YSTTVXH=$!M@)RZ#Z005:_7S5A$\>Q_@0
M'^!F/E)C78D ^**;XC^-R39\$2##Z>%ID1X6CQ 4'1K)24AU<&03Z^!(/CR*
M\XDZWY]I9.PIB,\UD]A^*?GS%'>C7VH_L\SRRV]GS\QS*P1"R!5&D!U<"^KJ
M*WFOJ:)$7WX^8H!%/2_]H&J:..CH$(7H#Z]Z:2;IF.QP GAPF56\X+G7J=67
MNM#6Z[R]..]_[-[S_;Q]S),M?B$LR?7\'7.1QOG;YJ/6'%EYL3\E+HWQF$GG
MS-)<69*"DL SHJCD8T0#-J+^$-,O.)#>"M(&F 6*,2FEAZ.Q&H4"F/.^N:1#
MN;KS)X(V%O\5;.?^5,$.1)5KM:^1=5B[1U0/;8_HM;N=BW/2_[W=/;]J?^QW
M6CV("BY:A2^-TK]N&/[$1?=;!9Q/M01X.M-X]N.=RF,^GO>X OU]TO??IHT=
M<.#+,Z,':W %$[E;L%>41?(6MJU03$FO0%JQ&-&U";?G,=O'U]_MD\ZT1IP-
M%TX-+O4W+<3A0>)B\@EY_=GYYO\!4$L#!!0    ( $B!"UO-P08N9@(   @'
M   0    <V5R+3(P,C4P.#$Q+GAS9,U4R6[;,!"]^RM8G4LM7B7#=H Z"%#
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MJ3WB:%AU&JKCU;W0';.+0MGA3YD,;=@K>S"B^**U&5D4)2S&V/0>"BE @E-
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MD),1<Q)\1Y-F40VF2BBLPV1CUPE"U$)@S<A]Y$,F)0;E44H72-M@P'QX@X5
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M"@M'^_I%"+SVK&@,2\4?#RP_0,_X.#_=!+P$"0$N^Z12XE >WOTXLHP1H,F
M1T;PO9BA#"<"\EZO0A1IV^C)J/&?R HXFD:__<D'I.G:Y,L$F$2Z\%V_CR.
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M<WM*MQ  B#2JW$[*VV+X8.>HD9:Q@=S<LXP$%N*?B(E('T@I_D4>P;"@<I9
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M<RPXKB>W*J6<NX/P$0B20GGI5'V10#:HCE3;V01DMF6V()GY 8T+9(C(:PY
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MLS-</& P#/QP=IR+>^&ETV=%/"_& UL05_#9*!]C"'2X+8>/7-_DJ0>04,
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M"Y<'02PO;\(_Y^&V.. T35[-QQ5A,FBU@D4(C1[-'23!@@#-##L"KD:T3T"
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M2P$"% ,4    " !(@0M;S<$&+F8"   (!P  $               @ &L#@
M<V5R+3(P,C4P.#$Q+GAS9%!+ 0(4 Q0    ( $B!"UM#[!OQ60H  !19   4
M              "  4 1  !S97(M,C R-3 X,3%?;&%B+GAM;%!+ 0(4 Q0
M   ( $B!"UMVQQ6[V@8   ,S   4              "  <L;  !S97(M,C R
M-3 X,3%?<')E+GAM;%!+ 0(4 Q0    ( $B!"ULE!K08]2L  .QF @ >
M          "  =<B  !S97(M,C R-3 X,3%X97@Y.3%?96%R;FEN9RYH=&U0
52P4&      4 !0!, 0  "$\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ser-20250811_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ser-20250811.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708599</identifier>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001708599</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Serina Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-38519</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">82-1436829</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">601 Genome Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 2001</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Huntsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">35806</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">(256)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">327-9630</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">SE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2025-08-11</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-25">2025-08-11</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
